DANIEL DISALVO: Open Payments
NPI 1255520441 · GRANDVIEW HEIGHTS, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,919 in 128 payments from 12 companies in 2025. Trend: 2023 $10,508 · 2024 $5,060 · 2025 $7,919
Speaker / faculty: $4,125Food & beverage: $2,545Consulting: $750Travel & lodging: $499
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $4,997 |
| Alkermes, Inc. | 17 | $1,097 |
| Axsome Therapeutics, Inc. | 19 | $473 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $362 |
| Neurocrine BioSciences, Inc. | 8 | $287 |
| E.R. Squibb & Sons, L.L.C. | 5 | $286 |
| Supernus Pharmaceuticals, Inc. | 10 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $94 |
| Otsuka America Pharmaceutical, Inc. | 3 | $80 |
| Lundbeck LLC | 2 | $37 |
Products named: VRAYLAR, ARISTADA, Auvelity, CAPLYTA, INGREZZA, COBENFY, Qelbree, REXULTI.
Industry payments across OH — which companies pay providers there.
